TRCT
CDIO icon

Tower Research Capital (TRC)’s Cardio Diagnostics CDIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96K Sell
1,809
-383
-17% -$724 ﹤0.01% 4447
2026
Q1 		$4.27K Buy
2,192
+1,415
+182% +$3.7K ﹤0.01% 4213
2025
Q4 		$2.11K Sell
777
-11
-1% -$40 ﹤0.01% 4584
2025
Q3 		$3.16K Buy
788
+688
+688% +$2.72K ﹤0.01% 4540
2025
Q2 		$360 Sell
100
-505
-83% -$3.78K ﹤0.01% 5050
2025
Q1 		$5.99K Buy
605
+354
+141% +$5.51K ﹤0.01% 4075
2024
Q4 		$6.9K Buy
251
+89
+55% +$1.23K ﹤0.01% 4131
2024
Q3 		$1.08K Sell
162
-30
-16% -$368 ﹤0.01% 5209
2024
Q2 		$3.16K Buy
192
+58
+43% +$1.36K ﹤0.01% 4926
2024
Q1 		$5.72K Buy
134
+41
+44% +$2.34K ﹤0.01% 4502
2023
Q4 		$6.92K Sell
93
-231
-71% -$7.99K ﹤0.01% 4685
2023
Q3 		$3.3K Buy
324
+139
+75% +$3.34K ﹤0.01% 5024
2023
Q2 		$6.6K Buy
185
+142
+330% +$8.01K ﹤0.01% 4678
2023
Q1 		$5K Buy
+43
New +$3.39K ﹤0.01% 4938
2022
Q4 		– Sell
-1
Closed – – 5927
2022
Q3 		$0 Hold
1
– – ﹤0.01% 6090
2022
Q2 		$0 Buy
+1
New +$298 ﹤0.01% 6099
2022
Q1 		– Hold
0
– – – 6122

Other funds holding CDIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s CDIO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Cardio Diagnostics (CDIO) stake by 17% in Q2 2026, selling an estimated $724 and leaving 1,809 shares worth $3.96K. The position accounts for ﹤0.01% of the portfolio, ranked #4447.

Tower Research Capital (TRC) first reported a position in CDIO in Q2 2022 and has held it in 16 quarters since. The position peaked at $6.92K in Q4 2023. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • Tower Research Capital (TRC) held 1,809 shares of Cardio Diagnostics worth $3.96K as of Q2 2026.
  • Tower Research Capital (TRC) sold 383 Cardio Diagnostics shares in Q2 2026, an estimated $724.
  • Cardio Diagnostics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4447 holding.
  • Tower Research Capital (TRC) first reported a position in Cardio Diagnostics in Q2 2022 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Cardio Diagnostics position peaked at $6.92K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.